TRPC6 is a Biomarker for Prognosis and Immunotherapy of Stomach Adenocarcinoma Based on Bioinformatic Analysis and Experimental Validation
This study highlights the prognostic significance of TRPC6 in STAD and its potential as a therapeutic target. TRPC6's involvement in immune regulation and cancer cell progression underscores its dual role in STAD pathogenesis and treatment, offering new avenues for targeted therapy development.
Authors
- ZhenXiong Ye
- Xingchi Hu (ORCID: https://orcid.org/0000-0003-3979-1957)
- Hongwei Wang (ORCID: https://orcid.org/0000-0003-2868-5112)
- Jingxin Zhang (ORCID: https://orcid.org/0000-0003-1740-2746)
- Zhenhua Huang (ORCID: https://orcid.org/0000-0002-8414-2772)
- Haitao Sun
Institutions
- Jiangsu University (CN)
- Tongji University (CN)
- Nantong University (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Yancheng First People's Hospital (CN)
- Nanjing University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/itt.s488953
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu University